Compare GNL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | NTLA |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 986.9M |
| IPO Year | N/A | 2016 |
| Metric | GNL | NTLA |
|---|---|---|
| Price | $8.46 | $9.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | $9.00 | ★ $19.83 |
| AVG Volume (30 Days) | 1.3M | ★ 4.1M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $751,333,000.00 | $57,528,000.00 |
| Revenue This Year | N/A | $1.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 17.63 | ★ 33.52 |
| 52 Week Low | $6.51 | $5.90 |
| 52 Week High | $8.49 | $28.25 |
| Indicator | GNL | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 41.47 |
| Support Level | $8.20 | $8.90 |
| Resistance Level | $8.40 | $9.68 |
| Average True Range (ATR) | 0.13 | 0.52 |
| MACD | 0.02 | 0.37 |
| Stochastic Oscillator | 96.84 | 59.25 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.